Getting your player ready...
WASHINGTON — Federal health advisers said anemia drugs sold by Amgen Inc. and Johnson & Johnson should only be used by a limited segment of chemotherapy patients — a restriction that could cost the companies millions.
The limits, proposed Thursday by a Food and Drug Administration advisory panel, were the latest blow to three blockbuster medications already plagued by concerns over increased risks of death and tumor growth.
